Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ataxin-2 is a highly conserved RNA-binding protein encoded by the ATXN2 gene. It plays multiple roles related to RNA metabolism, including mRNA translation, splicing, and stability. It is involved in the formation of stress granules and P-bodies. Expansion of a polyglutamine (polyQ) tract within Ataxin-2 causes Spinocerebellar Ataxia Type 2 (SCA2), and intermediate-size expansions are associated with increased ALS risk. It also negatively regulates endocytic EGFR internalization at the plasma membrane and is essential for synapse-specific long-term plasticity. Variants or dysfunctions have also been linked to primary open-angle glaucoma, Parkinson’s disease, obesity and type I diabetes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ataxin-2.